Advisors Preferred’s Vir Biotechnology VIR Stock Holding History

Advisors Preferred’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-19,413	Closed	-$484K	–	260
2022 Q4	$484K	Buy	+19,413	New	+$476K	0.21%	72

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Advisors Preferred's VIR Position: Q1 2023 in Review

Advisors Preferred sold out of Vir Biotechnology (VIR) in Q1 2023, closing a stake of 19,413 shares — an estimated $484K sold.

Advisors Preferred first reported a position in VIR in Q4 2022 and held it in 1 quarter. The position peaked at $484K in Q4 2022. 232 funds tracked by Wall St. Rank hold VIR as of Q1 2023.

Advisors Preferred reported no remaining Vir Biotechnology position as of Q1 2023 after selling out during the quarter.
Advisors Preferred sold 19,413 Vir Biotechnology shares in Q1 2023, an estimated $484K.
Advisors Preferred first reported a position in Vir Biotechnology in Q4 2022 and held it in 1 quarter.
Advisors Preferred's Vir Biotechnology position peaked at $484K in Q4 2022.
232 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2023.

Based on Advisors Preferred's 13F filing for Q1 2023, filed 3 May 2023.